Video

Dr. Tolba on Targeting NRG1 Fusions in NSCLC

Author(s):

Khaled A. Tolba MD, MBBCh
Conference|IASLC World Conference on Lung Cancer

Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, provides data from a study on targeting NRG1 fusions in non-small cell lung cancer.

Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, provides data from a study on targeting NRG1 fusions in non—small cell lung cancer (NSCLC).

Recently presented during the 2019 World Conference on Lung Cancer, Tolba’s research shows that afatinib (Gilotrif) has activity in NRG1-fusion positive NSCLC. This adds to other research, however, a study with a larger cohort is suggested for the future.

<<< 2019 World Conference on Lung Cancer

Related Videos
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Marshall Posner, MD
Renee Saliby, MD, MSc
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Related Content
Caicun Zhou, PhD, MD, of Shanghai Pulmonary Hospital and Tongji University School of Medicine in Shanghai, PR China
September 11th 2023

IMpower151 Misses Primary PFS End Point With Frontline Atezolizumab Plus Bevacizumab/Chemo in NSCLC

Byoung Chul Cho, MD, PhD
September 11th 2023

Baseline Characteristics Not Tied to Benefit With Durvalumab/Tremelimumab and Chemo in Metastatic NSCLC

Lung Cancer © stock.adobe.com
September 11th 2023

Perioperative Durvalumab Plus Chemo Yields Responses, EFS Benefit in Resectable NSCLC

David H. Harpole, MD
September 11th 2023

Neoadjuvant Durvalumab Plus Chemo Followed by Adjuvant Durvalumab Does Not Provide Benefit for EGFR+ NSCLC

Noboru Yamamoto, MD, PhD
September 11th 2023

Zongertinib Proves Clinically Active With Low Rate of EGFR-Mediated AEs in HER2-Mutant Solid Tumors

Solange Peters, MD, PhD
September 11th 2023

Durvalumab Associated With Lower Real-World PFS in EGFR-Mutated NSCLC Vs EGFR Wild-Type NSCLC